Effects of NT-0796 in Obese Participants at Risk of Cardiovascular Disease - Trial NCT06129409
Access comprehensive clinical trial information for NCT06129409 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by NodThera Limited and is currently Recruiting. The study focuses on Cardiovascular Diseases. Target enrollment is 69 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
NodThera Limited
Timeline & Enrollment
Phase 1/2
Oct 10, 2023
Apr 01, 2024
Primary Outcome
Change in hsCRP levels
Summary
This trial is a Randomized, Double-Blind (Sponsor-Open), Placebo-Controlled Study to Assess
 the Effect of NT-0796 on Inflammation in Obese Participants at Risk of Cardiovascular
 Disease.
 
 Participants will be admitted to an in-patient Clinical Research Unit on Day -1 and will be
 discharged on Day 30. The trial will include a 7-day out-patient safety follow-up period
 following the last dose of study treatment.
 
 For the first approximately 20 participants effect of food will be evaluated on the
 Pharmacokinetics of NT-0796. MRI's will be conducted in a subset of participants.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06129409
Non-Device Trial